Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 06:00 ET | Source: Traws Pharma, Inc.

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with...
November 13, 2025 07:00 ET | Source: Traws Pharma, Inc.

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual...
October 14, 2025 07:00 ET | Source: Traws Pharma, Inc.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment ...
October 06, 2025 07:00 ET | Source: Traws Pharma, Inc.

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to...